Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
María Teresa Herrera-Abreu(Institute of Cancer Research), Nicholas C. Turner(Royal Marsden NHS Foundation Trust)
Cited by 28
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2022|633
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
|Clinical Cancer Research|2010|323
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
|Nature Communications|2020|258